Enzymotec (ENZY) Misses Q3 EPS by 4c; Trims FY16 Outlook; CEO Katz Resigns
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enzymotec Ltd. Announces Departure of its CEO
November 16, 2016 7:30 AM ESTMIGDAL HA'EMEQ, Israel, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq: ENZY) ("Enzymotec" or the "Company"), a developer, manufacturer and marketer of innovative bio-active lipid based nutritional ingredients and medical foods, today announced that Dr. Ariel Katz, the Companys President and Chief Executive Officer, will depart the Company by the end of May 2017, and the Board of Directors has initiated a search for a permanent replacement.
We would like to thank Ariel for his commitment to the Company for the past 17 years; his leadership was instrumental to the... More
Enzymotec Ltd. Reports Third Quarter 2016 Unaudited Financial Results
November 16, 2016 7:30 AM ESTNutrition Segment increased Adjusted EBITDA* to $4M, representing 27% year-over-year and 17% sequential growth
VAYA Pharma sales to patients grew 45% year-over-year, but inventory destocking by wholesalers driven by the rapid adoption of VAYAs online pharmacy negatively impacts EPS by $0.05
MIGDAL HA'EMEQ, Israel, Nov. 16, 2016 (GLOBE NEWSWIRE) -- Enzymotec Ltd. (Nasdaq: ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients and medical foods, today reported financial results for the third quarter ended September 30, 2016.
Third Quarter 2016 Financial and Operational... More
